Systematic review of the effects of pomegranate (Punica granatum) on osteoarthritis

Aida Malek Mahdavi1*, Zeinab Javadivala2

1Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2Department of Health Education & Promotion, Faculty of Health, Tabriz University of Medical Sciences, Tabriz, Iran

Abstract

Background: Considering limitations of the established osteoarthritis (OA) medications, attention to adjuvant and complementary treatments has increased in OA individuals. Recent investigations have reported advantages of pomegranate in OA and indicate that pomegranate can be a therapeutic option; nevertheless, no systematic review exists regarding OA and pomegranate. Therefore, we systematically studied accessible researches regarding pomegranate and OA in human, animal, and in vitro models and likely mechanistic pathways.

Methods: Present systematic review study was recorded on the international prospective register of systematic reviews database. Electronic databases (Scopus, PubMed, Embase, WOS, ProQuest) and search engine Google Scholar were searched until February 2021. Search alerts were turned on to recognize papers published following the primary search. Two investigators independently searched using MESH and non-MESH words in title, abstract, and keywords. Inclusion criteria were related clinical, animal, and in vitro studies published in any language as a full text. Exclusion criteria were reviews, book chapters, conference abstracts, and articles regarding pomegranate in health problems other than OA. Hand searching was used to check the references or citations of eligible papers and grey literature (theses etc.) to find potential researches.

Results: Twenty-three articles were included in our systematic review. Human, animal, and in vitro researches demonstrated favorable properties of pomegranate in improving clinical features and reducing inflammatory, oxidative stress, and apoptosis markers in OA.

Conclusion: Present paper provides convincing evidence about the efficacy of pomegranate in OA and gives a justification for the importance of additional clinical studies.

Introduction

Osteoarthritis (OA) is a common musculoskeletal disorder and a main reason of disability worldwide.¹ The number of subjects disabled by OA has increased significantly in recent decades.² OA can affect different joints in body like hand, knee, and hip leading to pain, stiffness, swelling, and physical dysfunction.³ OA is a multifactorial disease and some important risk factors include age, sex, genetic, obesity, and joint injury.⁴ OA causes articular cartilage erosion, synovial membrane inflammation, and subchondral bone resorption.⁵ These pathological alterations are linked with an excessive generation of proinflammatory parameters like tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), which disarrange the balance among synthesis and degradation of matrix components leading to progressive joint destruction.⁵ In addition, pro-inflammatory cytokines induce oxidative stress and apoptosis in OA.⁶ High concentrations of reactive oxygen species (ROS) modulate numerous signaling pathways initiated by cytokines and further augment inflammatory, catabolic, and apoptotic reactions in chondrocytes causing cartilage matrix destruction.⁷ Because oxidative stress and apoptotic signaling pathways have an indispensable role in OA pathogenesis, therefore it is logical to assume that attenuation of these pathways can be helpful for managing OA.

There is no apparent cure for OA and currently available therapies are non-steroidal anti-inflammatory drugs (NSAIDs) with less effectiveness that cannot prevent or reverse cartilage destruction. Moreover, these medications have numerous side effects.⁶ Thus, considering limitations of the established OA medications, the use of complementary treatments has increased in OA individuals.⁹

Medicinal herbs are used for formulating therapeutic agents and have gained lots of attention due to treating...
different disorders particularly OA. Moreover, polyphenols, organic compounds in vegetables and fruits, have become a field of notice. Polyphenols possess anti-inflammatory and antioxidant features and exert preventive and/or therapeutic properties in health conditions. Pomegranate or Punica granatum L. is a medicinal herb that belongs to the family Punicaceae and can grow in various climates. Pomegranate has three major parts including peel, aril, and seed and each part possesses different nutrients and phytochemicals. Plenty of phenolic compounds, minerals, and complex carbohydrates present in the pomegranate peel. Monosaccharaides, malic, ascorbic, and citric acids, pectin, and some bioactive factors such as phenolics and flavonoids are found in the pomegranate arils. High concentrations of fatty acids including palmitic, stearic, linoleic, oleic, and punicic acids together with protein, sugars, fiber, pectin, minerals, vitamins, and polyphenols are found in the pomegranate seeds. Pomegranate juice is another important product obtained from whole fruit or arils.

Pomegranate possesses antioxidant, anti-inflammatory, anti-diabetic, anti-hypertensive, lipid-lowering, and anti-cancer characteristics and has been used as a medicinal herb since thousands of years ago. Phenolic compounds are the significant agents in pomegranate responsible for therapeutic properties. Also, animal and human researches did not indicate any undesirable outcomes after pomegranate intake. Experimental studies and clinical trials investigated the beneficial properties of pomegranate in OA prevention and treatment. Nevertheless, no systematic review exists regarding pomegranate and OA; therefore, in present article, we systematically studied accessible researches regarding pomegranate and OA in human, animal, and in vitro models and likely mechanistic pathways.

Materials and methods

Protocol

We performed current systematic review based on the preferred declaring items for systematic reviews and meta-analysis recommendations. We recorded the study protocol on the international prospective register of systematic reviews (PROSPERO) database (http://www.crd.york.ac.uk/PROSPERO), with a code CRD42021239810.

Strategy of search

Two investigators (AMM and ZJ) who had an experience and qualification in conducting systematic review studies, publishing different systematic review papers, and were familiar with search strategy, blind with each other and independently searched following electronic databases until February 2021: Scopus, PubMed, Embase, WOS, ProQuest, and a Google Scholar search engine. Also, search alert services in each database were turned on to recognize papers published following the primary search. Two investigators performed their search without any limitation in publication date and/or language using these MESH and non-MESH words in title, abstract, and keywords: “pomegranate”, “pomegranates”, “punica granatum”, “pomegranate juice”, “pomegranate extract”, “punicaeae”, “puna”, “granatum” together with “osteoarthritis”, “osteoarthritides”, “osteoarthritis”, “osteoarthroses”, “arthritis, degenerative”, “arthritides, degenerative”, “degenerative arthritides”, “degenerative arthritis”, “arthrosis”, “arthroses”, “osteoarthritis deformans”. Complete strategy of search for each database was provided in Table 1.

Selection of papers and extraction of data

Figure 1 depicts the flowchart of review stages. Two investigators blind with each other and independently searched the above-mentioned databases and entered the results of each database to the EndNote software. Then, duplicate papers (n = 79) were identified and removed by using the EndNote software. Afterwards, two investigators blind with each other and independently screened the papers (n = 76) to find the eligible studies. The inclusion criteria were related in vitro, animal, and clinical researches published in any language as a full text article. The exclusion criteria were reviews, book chapters, conference abstracts, and articles regarding pomegranate in health problems other than OA. Out of 76 papers that were screened, only 32 likely relevant papers remained. Ultimately, out of 32 likely relevant papers, nine papers were deleted due to ineligible study design, abstracts in conferences, pomegranate in combination with other herbs, and no accessible full-text. We could not find the full texts of two related papers and although we contacted with the corresponding authors for several times, we did not get any response and removed these papers. Therefore, 23 articles were considered for data extraction. Hand searching was also used to check the references or citations of these papers and grey literature (theses etc.) to find any potential researches. Although two investigators performed their search without any limitation in language, they did not find any non-English papers. During data extraction from these eligible papers, two investigators were blind with each other. Following data were gathered from the selected articles: first author’s surname, year of publication, subjects’ features, type and dose of pomegranate, duration of treatment, and outcomes. Overall, two investigators agreed with each other about selecting articles and extracting data and minor variations were corrected by reassessing data and consulting with the third person. Selected articles were illustrated in Tables 2–4.

Risk of bias assessment

We performed risk of bias assessment by Checklist for Reporting In-vitro Studies (CRIS) instruction for
Table 1. Search strategy used for electronic databases

| Database | Number of papers | Search Strategy |
|----------|-----------------|----------------|
| PubMed   | 18              | (TITLE-ABS-KEY (pomegranate) OR TITLE-ABS-KEY (pomegranates) OR TITLE-ABS-KEY (pomegranate juice) OR TITLE-ABS-KEY (pomegranate extract) OR TITLE-ABS-KEY (punica) OR TITLE-ABS-KEY (granutum)) AND (MINSUBJECT('Pomegranate') OR MINSUBJECT('Pomegranates') OR MINSUBJECT('Pomegranate juice') OR MINSUBJECT('Pomegranate extract')) |
| Scopus   | 45              | (TITLE-ABS-KEY (pomegranate) OR TITLE-ABS-KEY (pomegranates) OR TITLE-ABS-KEY (pomegranate juice) OR TITLE-ABS-KEY (pomegranate extract) OR TITLE-ABS-KEY (punica) OR TITLE-ABS-KEY (granutum)) AND (MINSUBJECT('Pomegranate') OR MINSUBJECT('Pomegranates') OR MINSUBJECT('Pomegranate juice') OR MINSUBJECT('Pomegranate extract')) |
| ISI      | 27              | (TS = 'pomegranate' OR TS = 'pomegranates' OR TS = 'pomegranate juice' OR TS = 'pomegranate extract' OR TS = 'punica' OR TS = 'granatum') AND (MINSUBJECT('Pomegranate') OR MINSUBJECT('Pomegranates') OR MINSUBJECT('Pomegranate juice') OR MINSUBJECT('Pomegranate extract')) |
| Embase   | 48              | (TITLE-ABS-KEY (pomegranate) OR TITLE-ABS-KEY (pomegranates) OR TITLE-ABS-KEY (pomegranate juice) OR TITLE-ABS-KEY (pomegranate extract) OR TITLE-ABS-KEY (punica) OR TITLE-ABS-KEY (granutum)) AND (MINSUBJECT('Pomegranate') OR MINSUBJECT('Pomegranates') OR MINSUBJECT('Pomegranate juice') OR MINSUBJECT('Pomegranate extract')) |
| Proquest | 2               | (MINSUBJECT('Pomegranate') OR MINSUBJECT('Pomegranates') OR MINSUBJECT('Pomegranate juice') OR MINSUBJECT('Pomegranate extract')) |

Figure 1. Flowchart of screening and choosing eligible studies

Records identified through database searching (n = 140)
Records after duplicates removed (n = 76)
Records screened (n = 76)
Records excluded (n = 44)
Full-text articles assessed for eligibility (n = 32)
Studies included in qualitative synthesis (n = 23)
Additional records identified through other sources (n = 15)
Full-text articles excluded (n = 9)
Because:
- Ineligible study design (n = 1)
- Abstracts in conferences (n = 4)
- No available full-text (n = 2)
- Pomegranate in combination with other herbs (n = 2)
vivro researches, SYRCLE’s risk of bias tool for animal researches, and Cochrane Collaboration’s tool for clinical researches, respectively. 46 Figure 2 presents the results of risk of bias evaluation.

Results

Study characteristics

Based on Figure 1, we noticed 155 papers. After removing duplicate articles, 76 articles remained that were screened based on titles and abstracts. Then, we excluded 44 review or unrelated articles. Ultimately, out of 32 likely relevant papers, nine papers were deleted due to unqualified study design (n = 1), abstracts in conferences (n = 4), and no accessible full-text (n = 2). Hence, 23 articles were included in present systematic review, which were clinical (n = 5), animal (n = 6), and in vitro (n = 7). In five articles, both animal and in vitro designs were detected. 24,25,27,28,47 Tables 2-4 demonstrated details of investigations.

Human studies

Table 2 presents human studies entered in this systematic review.

Clinical findings

In a study on female knee OA patients, Rafraf et al reported that consuming pomegranate peel hydro-alcoholic extract capsules (1 g/day) for 8 weeks significantly increased scores of knee injury and osteoarthritis outcome score (KOOS) and its subscales in comparison with placebo group, whereas visual analog scale (VAS) decreased significantly in comparison with placebo group. In another study in knee OA patients, Ghoochani et al 40,42 indicated that drinking 200 mL/day pomegranate juice for 6 weeks did not cause significant changes neither in physical function compared with placebo group.

Laboratory findings

In a study on female knee OA patients, Khadem Haghighian et al 40 reported that consuming pomegranate peel hydro-alcoholic extract capsules (1 g/day) during 8 weeks led to

| Table 2 Characteristics of human studies about the effect of pomegranate on osteoarthritis |
|-----------------------------------------------|-----------------|---------------------|-----------------|-----------------|-----------------|-----------------|
| Author (date) | Country | Subjects | Intervention | Dosage | Route | Duration | Clinical Findings | Laboratory Findings | Reference |
|----------------|---------|----------|--------------|--------|-------|---------|-------------------|---------------------|-----------|
| Khadem Haghighian et al (2020) | Iran | Female knee OA patients (n = 33 per group) | Pomegranate peel hydro alcoholic extract capsules | 1 g/day | Orally | 8 weeks | (1) Significant decrease in serum MDA levels compared with placebo group (2) Significant increase in SOD, GPx, and serum TAC levels compared with placebo group | - | 40 |
| Rafraf et al (2017) | Iran | Female knee OA patients (n = 33 per group) | Pomegranate peel hydro alcoholic extract capsules | 1 g/day | Orally | 8 weeks | (1) Significant increase in scores of KOOS and its subscales compared with placebo group (2) Significant decrease in VAS compared with placebo group | - | 41 |
| Khadem Haghighian et al (2016) | Iran | Female knee OA patients (n = 19 per group) | Pomegranate peel hydro alcoholic extract capsules | 1 g/day | Orally | 8 weeks | - | Significant decrease in serum hs-CRP level compared with placebo group | 42 |
| Ghoochani et al (2015) | Iran | Knee OA patients (n = 19 per group) | Pomegranate juice | 200 mL/day | Orally | 6 weeks | (1) No significant change in WOMAC total and subscales scores compared with placebo group (2) Significant increase in GPx concentrations compared with placebo group | (1) Significant reduction in serum MMP-1 and MMP-13 concentrations compared with placebo group (2) Significant increase in GPx compared with placebo group | 43 |
| Ghoochani et al (2015) | Iran | Knee OA patients (n = 19 per group) | Pomegranate juice | 200 mL/day | Orally | 6 weeks | No significant change in physical function compared with placebo group | No significant change in serum TNF-a and IL-1β levels compared with placebo group | 44 |

OA: osteoarthritis; MDA: malondialdehyde; SOD: superoxide dismutase; GPx: glutathione peroxidase; TAC: total antioxidant capacity; KOOS: knee injury and osteoarthritis outcome score; VAS: visual analog scale; hs-CRP: high sensitive-C reactive protein; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; MMP: matrix metalloproteinase; TNF-a: tumor necrosis factor-a; IL-1β: interleukin-1β.
| Author (date) | Population | Intervention | Dose | Route | Duration | Histologic Findings | Laboratory Findings | Reference |
|--------------|------------|--------------|------|-------|----------|---------------------|---------------------|-----------|
| Yang et al (2021) | 28 Days | Oral gavage | 28 | 35 Days | | | Significant improvement in disorder of chondrocyte differentiation in the growth plate zone compared with arthritic control group | 47 |
| Shivnath et al (2020) | 25 | Intragastric | 250 and 500 mg/kg BW | Oral | 30 Days | | Significant dose-dependent inhibition of DPPH activity compared with arthritic control group | 23 |
| Kong et al (2020) | 20 mg/kg BW | Oral gavage | 20 | 56 Days | | | Significant alleviation of OA symptoms and recovering the weight-bearing ratio at high dose (0.5 mg/kg BW) compared with arthritic control group | 24 |
| Elder et al (2020) | 9.2 mM twice a week | Knee injection | 9.2 mM | 35 Days | | | Significant decrease in knee swelling and cartilage matrix loss compared with arthritic control group | 25 |
| Fu et al (2019) | 20 mg/kg | Intragastric | 20 | 56 Days | | | Significant decrease in calcification of cartilage surface and lower narrow of joint space compared with arthritic control group | 27 |
| Lee et al (2018) | 15 and 150 mg/kg BW | Oral | 15 and 150 mg/kg BW | 28 Days | | | Significant alleviation of OA symptoms and recovering the weight-bearing ratio at high dose (150 mg/kg BW) compared with arthritic control group | 28 |
| Lee et al (2018) | 0.25 and 0.5 mg/kg BW | Oral | 0.25 and 0.5 mg/kg BW | 28 Days | | | Significant alleviation of OA progress during the initiation of knee cartilage degradation at high dose (150 mg/kg BW) compared with arthritic control group | 28 |
Table 3. Continued

| Author (date)          | Population | Intervention | Dose          | Route       | Duration | Histologic Findings                                                                 | Laboratory Findings                                                                 | Reference |
|------------------------|------------|--------------|---------------|-------------|----------|------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-----------|
| Choi et al. (2018)     | Surgically-induced OA rats (n = 90) | Pomegranate concentrated powder | 200 mg/kg BW | Orally | 58 Days | (1) Significant decrease in knee thickness, capsule-exposed knee thickness, maximum extension angle of the knee, OA-like X-ray signs, number of synovial membrane BrdU-immunoreactive cells, femoral and tibial articular cartilage Mankin scores, synovial membrane epithelial lining thickness, number of inflammatory cells that infiltrate the synovial membrane, number of PARP-immunolabeled cells in femoral and tibial articular cartilage and synovial membrane, COX-2- and TNF-a-immunoreactive cells of femoral and tibial articular cartilage and synovial membrane compared with arthritic control group  | (1) Significant decrease in femoral and tibial articular cartilage with synovial membrane PGE2 levels, 5-LPO activity of femoral and tibial articular cartilage with synovial membrane, femoral and tibial articular cartilage with synovial membrane COL-2 mRNA expression compared with arthritic control group | 29        |
| Choi et al. (2017)     | Surgically-induced OA rats (n = 140) | Pomegranate concentrated powder | 200 mg/kg BW | Orally by gastric gavage | 28 Days | (1) Significant decrease in knee thickness, capsule-exposed knee thickness, maximum extension angle of the knee, number of synovial membrane BrdU-immunoreactive cells, femoral and tibial articular cartilage Mankin scores, synovial membrane lining epithelium thickness, number of inflammatory cells infiltrating the synovial membrane tissue, numbers of PARP, COX-2, and TNF-a-immunoreactive cells in femoral and tibial articular cartilage with synovial membrane tissue compared with arthritic control group  | (1) Significant decrease in PGE2 levels, 5-LPO, MMP-2, and MMP-9 activities in femoral and tibial articular cartilage with synovial membrane tissue, COL-2 mRNA expression in synovial membrane tissue compared with arthritic control group | 30        |
| Akhtar et al. (2017)   | Surgically-induced OA rabbits (n = 27) | Pomegranate fruit extract in water | 34 mg/kg BW | Orally | 56 days and 70 days | (1) Significant decrease in disease severity grades of macroscopic articular cartilage lesions in joint compartments, mean score for the loss of Safranin-O staining, structural changes, and cluster formation, total histological score and scores for histological parameters, number of cells with active caspase-3 and PARP p85 in cartilage and caspase-mediated apoptosis pathway contributing to cartilage pathology compared with arthritic control group  | (1) Significant decrease in MMP-3, MMP-9, and MMP-13 expression and PGE2 level in synovial fluid compared with arthritic control group  | 31        |
| Hadipour-Jahromy et al. (2010) | MIA-induced OA mice (n = 30) | Pomegranate juice | 4, 10, and 20 mL/kg BW | Orally | 14 days | (1) Significant prevention from chondrocyte damage compared with arthritic control group  | (2) Significant inhibition of circulating plasma and synovial fluid MMP-13 and synovial fluid IL-6 levels compared with arthritic control group  | 32        |
Table 4. Characteristics of in vitro studies about the effect of pomegranate on osteoarthritis

| Author (date) | Population | Intervention | Dose | Duration | Findings |
|---------------|------------|--------------|------|----------|----------|
| Yang et al (2021) | TNF-α and IL-1β-induced chondrocytes as a model of OA | Punicalin | 0-100 μg/mL | 24 Hours | (1) Protection against growth inhibition of chondrocytes and impeding chondrocyte apoptosis  
(2) Blocking phosphorylation and cytoplasmic transfer of FOXO3 protein level  
(3) Decrease MMP-9, COL10A1, Runx2, IHH, and PTHLH mRNA expression  
(4) Up-regulation of Sox-9 and COL2A1 mRNA expression  
(5) No change in COL9A1, MMP-13, Runc3 mRNA expression |
| Lin et al (2020) | Human OA chondrocytes | Ellagic acid | 12.5, 25, 50 μM | 24 Hours | (1) Protection against growth inhibition of chondrocytes and impeding chondrocyte apoptosis  
(2) Blocking phosphorylation and cytoplasmic transfer of FOXO3 protein level  
(3) Decrease MMP-9, COL10A1, Runx2, IHH, and PTHLH mRNA expression  
(4) Up-regulation of Sox-9 and COL2A1 mRNA expression  
(5) No change in COL9A1, MMP-13, Runc3 mRNA expression |
| Ding et al (2020) | IL-1β-induced rat chondrocytes as a model of OA | Urolithin A | 1, 7.5, 15 μM | 48 hours | (1) Protection against growth inhibition of chondrocytes and impeding chondrocyte apoptosis  
(2) Blocking phosphorylation and cytoplasmic transfer of FOXO3 protein level  
(3) Decrease MMP-9, COL10A1, Runx2, IHH, and PTHLH mRNA expression  
(4) Up-regulation of Sox-9 and COL2A1 mRNA expression  
(5) No change in COL9A1, MMP-13, Runc3 mRNA expression |
| Kong et al (2020) | TBHP-treated chondrocytes as a model of OA | Punicalagin | up to 50 μg/mL | 24-48 hours | (1) Protection against growth inhibition of chondrocytes and impeding chondrocyte apoptosis  
(2) Blocking phosphorylation and cytoplasmic transfer of FOXO3 protein level  
(3) Decrease MMP-9, COL10A1, Runx2, IHH, and PTHLH mRNA expression  
(4) Up-regulation of Sox-9 and COL2A1 mRNA expression  
(5) No change in COL9A1, MMP-13, Runc3 mRNA expression |
| Fu et al (2019) | Primary human OA chondrocytes | Urolithin A | 3, 10, or 30 μM | 24 Hours | (1) Protection against growth inhibition of chondrocytes and impeding chondrocyte apoptosis  
(2) Blocking phosphorylation and cytoplasmic transfer of FOXO3 protein level  
(3) Decrease MMP-9, COL10A1, Runx2, IHH, and PTHLH mRNA expression  
(4) Up-regulation of Sox-9 and COL2A1 mRNA expression  
(5) No change in COL9A1, MMP-13, Runc3 mRNA expression |
| Taherian et al (2018) | LPS-stimulated Bovine Fibroblast-like synoviocytes (BFLS) as a model of OA | Punicalagin | 1 μg/mL | 24 Hours | (1) Protection against growth inhibition of chondrocytes and impeding chondrocyte apoptosis  
(2) Blocking phosphorylation and cytoplasmic transfer of FOXO3 protein level  
(3) Decrease MMP-9, COL10A1, Runx2, IHH, and PTHLH mRNA expression  
(4) Up-regulation of Sox-9 and COL2A1 mRNA expression  
(5) No change in COL9A1, MMP-13, Runc3 mRNA expression |

Reference

47
25
33
24
27
34
Table 4. Continued

| Author (date) | Population | Intervention | Dose | Duration | Findings |
|---------------|------------|--------------|------|----------|----------|
| Lee et al (2018) | IL-1β-induced primary rat chondrocytes as a model of OA | POMx (70% acetone extract of pomegranate peels) | 12.5 to 100 μg/mL | 16 Hours | (1) Reduction in iNOS, MMP-13, and COX-2 protein expression in a dose-dependent manner (2) Reduction in IL-1β-induced PGE2 production |
| Lee et al (2018) | IL-1β-induced primary rat chondrocytes as a model of OA | Punicalagin | 6.25 to 50 μg/mL | 16 Hours | (1) Inhibition of iNOS, MMP-13, and COX-2 protein expression (2) Reduction in IL-1β-induced PGE2 production |
| Haseeb et al (2017) | Human OA chondrocytes | Pomegranate fruit extract | 50 μg/mL | 2 Hours | (1) Inhibition of IL-1β-induced mRNA and protein expression of IL-6 in a dose dependent manner (2) Suppression of the IL-1β-mediated generation of ROS (3) Inhibition of the IL-1β-induced activation and DNA binding activity of NF-κB p65 (4) Inhibition of the phosphorylation of IKKαβ and downregulation of the expression of IKKβ at protein and mRNA levels in a dose-dependent manner (5) Inhibition of the intrinsic and IL-1β induced phosphorylation of NIK |
| Choi et al (2017) | LPS- and rhIL-1α-stimulated rat chondrocytes as a model of OA | Dried pomegranate concentrate powders | 1 mg/mL | 24 Hours | (1) Inhibition of LPS-stimulated PGE2 production and 5-LPO activity (2) Inhibition of rhIL-1α-stimulated MMP-2 and MMP-9 activities (3) Up-regulation of mRNA expressions of ECM related chondrogenic genes such as collagen type II, Sox-9, and aggrecan |
| Haseeb et al (2013) | Human OA chondrocytes | Delphinidin | 10 and 50 μg/mL | 2 Hours | (1) Inhibition of IL-1β-induced expression of COX-2 mRNA and protein and the production of PGE2 (2) Suppression of IL-1β-induced activation and DNA binding activity of NF-κB p65 (3) Inhibition of IL-1β-induced phosphorylation and degradation of IκBα (4) Down-regulation of the protein and mRNA expressions of IKKβ (5) Inhibition of the activation of a kinase upstream of NIK and IL-1β-induced activation of NF-κB (6) Inhibition of the IL-1β-induced phosphorylation and degradation of IRAK1 |
| Rasheed et al (2010) | Primary human OA chondrocytes | Pomegranate extract | 6.25 to 100 μg/mL | 2 Hours | (1) Attenuation of the IL-1β-induced phosphorylation of both MKP-3 and MKP-6 in a dose dependent manner (2) Inhibition of IL-1β-induced phosphorylation of p38-MAPK and activation of p38α-MAPK (3) Inhibition of IL-1β-induced increase in the DNA binding activity of RUNX-2 transcription factor in a dose-dependent manner (4) No effect on binding of IL-1β with IL-1R |
| Ahmed et al (2005) | Human OA chondrocytes | Pomegranate fruit extract | 6.25-50 mg/mL | 24 Hours | (1) Blocking the effect of IL-1β on the viability of OA chondrocytes and IL-1β-induced cytotoxic effects (2) Inhibition of the IL-1β-induced upregulation of MMP-1, MMP-3, and MMP-13 mRNA levels (3) Inhibition of the IL-1β-induced production of MMPs 1, 3, 13 (4) Inhibition of the IL-1β-induced OA cartilage degradation (5) Inhibition of the IL-1β-induced phosphorylation of ERK, JNK, p38-MAPK, c-Jun, and ATF-2 (6) Inhibition of the DNA binding activity of NF-κB |

OA: osteoarthritis; FOXO3: Forkhead box O3; MMP: matrix metalloproteinase; COL10A1: Collagen Type X Alpha 1 Chain; RUNX-2: runt-related transcription factor-2; iHH: Indian Hedgehog Signaling Molecule; PTHLH: Parathyroid Hormone Like Hormone; Sox-9: SRY-box 9; COL2A1: Collagen Type II Alpha 1 Chain; COL9A1: Collagen Type IX Alpha 1 Chain; IL: interleukin; iNOS: inducible nitric oxide synthase; COX-2: cyclooxygenase-2; NO: nitric oxide; PGE2: prostaglandin E2; TNF: tumor necrosis factor; ADAMTS: A Disintegrin and Metalloproteinase with Thrombospondin motifs; ECM: extracellular matrix; IκBα: inhibitor of kappa Bα; NF-κB: nuclear factor kappa B; MAPK: mitogen-activated protein kinase; ERK1/2: extracellular signal-regulated protein kinase; JNK: c-Jun N-terminal Kinase; TBHP: Tert-butyl hydroperoxide solution; HO-1: heme oxygenase-1; SOD: superoxide dismutase; NQO: NAD(P)H quinone dehydrogenase; Bcl-2: B-cell lymphoma-2; OARSI: Osteoarthritis Research Society International; NIK: NF-κB-inducing kinase; IRAK1: IL-1 receptor-associated kinase-1; M KK: MAPK kinase; ATF-2: activated transcription factor-2.
significant reduction in serum malondialdehyde (MDA) and high sensitive C-reactive protein (hs-CRP) levels and significantly increased superoxide dismutase (SOD), glutathione peroxidase (GPx), and serum total antioxidant capacity (TAC) compared with placebo group. In another research on knee OA patients, drinking 200 mL/day pomegranate juice during 6 weeks significantly reduced serum matrix metalloproteinase (MMP)-1 and MMP-13 concentrations and considerably increased GPx compared to placebo; however, it did not cause significant changes in serum TNF-α and IL-1β in comparison with placebo.

**Animal studies**

Table 3 presents animal studies entered in this systematic review.

**Histologic findings**

Yang et al reported that 100 mg/kg body weight (BW) punicalin during 28 days considerably improved chondrocyte differentiation disorder in the growth plate area, promoted the formation of calcified cartilage area, and prevented from cell escape in the superficial area of tibia compared with arthritic control mice. Shivnath et al reported that 250 and 500 mg/kg BW Punica granatum L. peel extract for 30 days significantly decreased macroscopic lesion severity and cartilage histopathological score including lower severity in chondrocytes disorganization as well as lower surface cartilage erosion together with proteoglycan and collagen content retention in collagenase-induced OA rats in comparison with arthritic control rats. Significant suppression of collagen degradation and retention of proteoglycan content were also reported compared with arthritic control rats. In another research in collagenase-induced OA rats, Lee et al indicated that administration of POMx (70% acetone extract of pomegranate peels) for 28 days considerably alleviated OA progression during the initial stages of cartilage degradation as well as OA signs and improved the weight-bearing ratio at dose of 150 mg/kg BW in comparison with arthritic control rats. Moreover, punicalagin remarkably ameliorated thickening and hypercellularity of synovium, reduced synovitis score, decreased knee swelling and cartilage matrix loss and significantly alleviated cartilage breakdown in comparison with arthritic controls. Another study in surgical DMM-induced OA mice reported that 200 mg/kg BW pomegranate concentrated powder for 58 and 28 days significantly decreased knee thickness, capsule-exposed knee thickness, knee maximum extension angle, OA-like X-ray signs, number of synovial membrane 5-Bromo-2'-Deoxyuridine (BrdU)-immunoreactive cells, femoral and tibial articular cartilage Mankin scores, synovial membrane epithelial lining thickness, number of inflammatory cells infiltrating synovial membrane, number of cleaved poly ADP-ribose polymerase (PARP)-immunolabeled cells in the femoral and tibial articular cartilage and synovial membrane, and cyclooxygenase-2 (COX-2)- and TNF-α-immunoreactive cells of the femoral and tibial articular cartilage and synovial membrane compared with arthritic control group. In addition, significant increase was reported in total knee joint, femoral, and tibial articular surface bone mineral density (BMD), femoral and tibial articular cartilage focal compressive strength, number of femoral and tibial articular cartilage BrdU-immunoreactive cells, and thicknesses of femoral and tibial articular cartilage compared to arthritic controls. In another research in surgically-induced OA rabbits, Akhtar et al demonstrated that 34 mg/kg BW pomegranate fruit extract in water for 56 and 70 days significantly decreased severity grades of joint macroscopic articular cartilage lesions, loss of Safranin-O staining mean score, structural alterations and cluster formation, histological total and parameters scores, number of cells with active caspase-3 and PARP p85 in cartilage, and caspase-mediated apoptosis pathway causing cartilage pathology in comparison with arthritic control rabbits; however, no considerable trend toward increased density of chondrocyte was found in comparison with arthritic control group. Another research in MIA-induced OA mice reported that 4, 10, and 20 mL/kg BW pomegranate juice for 14 days significantly prevented chondrocyte damage and led to significant focal increase in number of cells together with less damage to epiphyseal plate proteoglycan compared with arthritic control mice.

**Laboratory findings**

Yang et al reported that 100 mg/kg BW punicalin for 28 days inhibited forhead box O3 (FOXO3) phosphorylation and cytoplastic transfer and elevated FOXO3 in TNF-α and IL-1β-induced OA mice compared with arthritic controls. Also, promotion of anabolism via up-regulating SKY-box 9 (Sox-9) and collagen type-II alpha 1 chain (COL2A1) as well as inhibition of catabolism via down-regulating collagen type X alpha 1 chain (COL10A1), MMP-9, MMP-13, runt-related transcription factor-2 (Runx2), Indian hedgehog signaling molecule (IHH), parathyroid hormone like hormone (PTHHLH) occurred compared with arthritic control mice. Shivnath et al reported that 250 and 500 mg/kg BW Punica granatum L. peel extract for 30 days caused significant dose-dependent suppression of 1,1-diphenyl-2-picrylhydrazyl (DPPH) activity in collagenase-induced OA rats compared to
arthritic controls. Also, remarkable decrease in serum alkaline phosphatase level and MMP-3 and COX-2 genes expression as well as significant increase in collagen type-II gene expression occurred compared with arthritic control rats. In a research in DMM-induced OA mice, Kong et al reported that 20 mg/kg BW punicalagin for 56 days significantly decreased intensity of cleaved caspase-3 and proportion of cellular apoptosis compared with arthritic control mice. In another study in surgical DMM-induced OA mice, Fu et al showed that 20 mg/kg Urolithin A for 56 days considerably ameliorated p-PI3K and p-AKT expression and decreased nuclear p65 expression compared with arthritic control mice. Other studies in surgically-induced OA rats reported that 200 mg/kg BW pomegranate concentrated powder for 58 and 28 days significantly decreased articular cartilage in femoral and tibial areas with synovial membrane prostataglandin E2 (PGE2) levels, 5-lipoxygenase (LPO) function of articular cartilage in femoral and tibial areas with synovial membrane, MMP-2 and MMP-9 activities of femoral and tibial articular cartilage with synovial membrane, and mRNA expression of synovial membrane collagen type-II in comparison with arthritic controls. Moreover, considerable elevation was observed in femoral and tibial articular cartilage collagen type-II mRNA expression as well as mRNA expression of Sox-9 and aggrecan in femoral and tibial articular cartilage with synovial membrane in comparison with arthritic control group.

In another research in surgically-induced OA rabbits, Akhtar et al stated that 34 mg/kg BW pomegranate fruit extract in water for 56 and 70 days significantly decreased expression of MMP-3, MMP-9, and MMP-13 and level of PGE2 in the synovial fluid compared with arthritic control rabbits. Furthermore, significant inhibition of plasma and synovial fluid MMP-13 concentrations as well as levels of IL-6 in synovial fluid was reported in comparison with arthritic control rabbits. Considerable increase in aggrecan and collagen type-II A1 expression was also found in comparison with arthritic controls; however, no remarkable alteration in synovial fluid IL-1β was noticed in comparison with arthritic controls.

**In vitro studies**

Table 4 presents in vitro studies entered in present review. Yang et al reported that 0-100 μg/mL punicalin for 24 hours protected TNF-α and IL-1β-stimulated chondrocytes against growth suppression and impeded chondrocyte apoptosis. The authors further suggested blocked phosphorylation and cytoplasmic transfer of FOXO3 protein level, decreased MMP-9, COL10A1, Runx2, IHH, and PTHLH mRNA expression as well as up-regulated Sox-9 and COL2A1 mRNA expression. However, no changes were reported in COL9A1, MMP-13, and Runx3 mRNA expression after punicalin treatment. According to Lin et al study on human OA chondrocytes, 12.5, 25, and 50 μM Ellagic acid inhibited IL-1β-stimulated production of inducible nitric oxide synthase (iNOS) and COX-2 and decreased nitric oxide (NO), PGE2, TNF-α, and IL-6 synthesis in a concentration-dependent way. The authors further reported suppressed generation of a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-5 and MMP-13 in a concentration-dependent way, inhibition of IL-1β-stimulated cytoplasmic collagen type-II degradation, amelioration of extracellular matrix (ECM) deterioration, and up-regulation of aggrecan and collagen type-II production in a dose-dependent manner. Reverse in inhibitor of kappa Ba (IkBa) protein production in cytoplasm, inhibition in p65 translocation into the nucleus, and suppression of the nuclear factor kappa B (NF-κB) pathway in a concentration-dependent manner were also reported. In a research on IL-1β-induced rat chondrocytes as an OA model, Ding et al reported that 1, 7.5, and 15 μM Urolithin A suppressed IL-1β-induced overproduction of MMP-9 and ADAMTS4 mRNA and decreased IL-1β-stimulated destruction of cartilage matrix dose-dependently. The authors further reported reverse in downregulated gene expression of collagen type-II dose-dependently, reduced MMP-3 and MMP-13 proteins expression, suppressed IL-1β-stimulated expression of iNOS and COX2 as well as IL-1β-stimulated breakdown of Sox-9, collagen II, and aggrecan dose-dependently. Suppression of upregulated phosphorylation of mitogen-activated protein kinase (MAPK) pathway members like extracellular signal regulated protein kinase (ERK1/2), c-Jun N-terminal Kinase (JNK), and p38 and inhibition of IL-1β-stimulated NF-κB activation in a concentration-dependent manner were also suggested. In a study on Tert-butyl hydroperoxide solution (TBHP)-treated chondrocytes as a model of OA, up to 50 μg/mL punicalin increased heme oxygenase-1 (HO-1), SOD1, and NAD(P)H quinone dehydrogenase 1 (NQO1) proteins expression and B-cell lymphoma-2 (Bcl-2) levels, whereas it lowered Bax levels, cleaved caspase-3, and decreased immunofluorescence intensity of cleaved caspase-3. Therefore, punicalin attenuated TBHP-stimulated oxidative stress and cell death. Furthermore, Kong et al suggested that punicalagin inhibited ADAMTS-5, MMP-3, and MMP-13 expression, thereby enhancing collagen type-II intensity and inhibiting ECM degradation. The authors further reported a smooth, proteoglycan-rich and hypercellularity cartilage surface, lower score for OARSI, enhanced autophagy, and amelioration in dysfunctional autophagic flux in TBHP-treated chondrocytes. Fu et al reported that 3, 10, or 30 μM Urolithin A inhibited up-regulation of IL-1β-stimulated mRNA and protein expression of iNOS and COX-2 and decreased NO, PGE2, IL-6, and TNF-α generation dose-dependently in primary human OA chondrocytes. Inhibition of stimulatory function of IL-1β on ADAMTS-5 and MMP-13 expression, reverse in suppressing effect of IL-1β on aggrecan and collagen type-II dose-dependently, suppression of IkBa degradation and...
bias was low. In a study on lipopolysaccharides (LPS)-induced primary rat chondrocytes as a model of OA, Lee et al.20 indicated that either 12.5 to 100 μg/mL POMx (70% acetone extract of pomegranate peels) or 6.25 to 50 μg/mL punicalagin decreased iNOS, MMP-13, and COX-2 proteins production dose-dependently and led to reduction in IL-1β-stimulated PGE2 production. Based on studies in human OA chondrocytes, pomegranate fruit extract dose dependently suppressed IL-1β-stimulated production of IL-6, production of ROS, activation and DNA binding function of NF-κB/p65, phosphorylation and expression of IKKβ, phosphorylation of NF-κB-inducing kinase (NIK), MAPK kinase-3 (MKK-3), MKK-6, p38-MAPK, and activation of p38α-MAPK.35,38,39 Furthermore, pomegranate fruit extract dose dependently decreased DNA binding activity of runt-related transcription factor-2 (RUNX-2), MMP-1, MMP-3, and MMP-13 production, cartilage degradation, and phosphorylation of ERK, JNK, c-Jun, and activated transcription factor-2 (ATF-2).35,38,39 In a research on LPS- and rhIL-1α-stimulated rat chondrocytes as a model of OA, Choi et al.36 showed that 1 mg/mL dried pomegranate concentrate powder inhibited LPS-stimulated PGE2 production and 5-LPO activity. Moreover, 1 mg/mL dried pomegranate concentrate powder inhibited rhIL-1α-stimulated MMP-2 and MMP-9 functions and up-regulated mRNA expression of ECM related chondrogenic genes including collagen type-II, Sox-9, and aggrecan.36 Haseeb et al.37 indicated that 10 and 50 μg/mL delphinidin inhibited IL-1β-stimulated COX-2 production and PGE2 generation, activation and DNA binding function of NF-κB p65, and phosphorylation and breakdown of IκBa in human OA chondrocytes. Moreover, down-regulation of IKKβ protein and mRNA expression, inhibition of a kinase upstream of NIK activation and IL-1β-stimulated NF-κB activation, and inhibition of IL-1β-induced phosphorylation and breakdown of IL-1 receptor-related kinase-1 (IRAK1) were reported.37

**Risk of bias and methodological quality**

Risk of bias was assessed for involved studies (Figure 2). An unclear risk of selection bias (because of lack of data regarding randomization method: n = 19 and concealment: n = 23); detection bias (blinding of outcome evaluation: n = 17); and attrition bias (n = 21) was shown. Reporting bias was low.

**Discussion**

Present study is the first systematic review assessing the available articles about pomegranate and OA in human, animal, and *in vitro* models. Pomegranate improved clinical symptoms40,41 as well as inflammatory and oxidative stress parameters42-44 in OA patients. Furthermore, animal and *in vitro* studies showed benefits of pomegranate in improving clinical features and reducing inflammatory and oxidative markers in OA.23-39,47 Discrepancy in findings on the clinical status and inflammatory markers between studies can be due to using different dosages, administration types, and preparation procedures.

Low-grade inflammation and oxidative stress are important in OA initiation and progression. Proinflammatory cytokines particularly IL-1β, IL-6, and TNF-α are the highly produced mediators in OA joints and have a critical function in degradation of articular cartilage matrix that makes them primary therapeutic target.48 Moreover, increase in concentrations of cytokines in joints stimulates the ROS and NO generation in chondrocytes and synoviocytes leading to increased oxidative stress, lack of balance between anabolic and catabolic processes in the cartilage matrix, chondrocytes apoptosis, and loss of cartilage.48 Therefore, scavenging ROS and blocking oxidative stress is another helpful approach for treating OA. Moreover, higher oxidative stress is harmful for chondrocyte survival.49 Recent investigations have indicated that decreasing oxidative stress is helpful for inhibiting apoptosis in chondrocytes and improving OA.26,51 One such plausible mechanisms for privileges of pomegranate in OA is anti-inflammatory properties. It appears that anti-inflammatory action of pomegranate is mainly related to phenolic agents (e.g. punicalagin, ellagic acid, anthocyanins) and fatty acids (e.g. punicic acid).13 Based on *in vitro* and animal studies, pomegranate inhibit COX and LPO enzymes that are responsible in developing the inflammatory pathways, thereby blocking the prostaglandin synthesis and inhibiting neutrophil activation.25,27-31,33,36,37 It has also been suggested that tannin in pomegranate called Granatin B suppresses COX-2 expression and PGE2 generation *in vitro*.52 Furthermore, pomegranate blocks the p38-MAPK pathway and the transcription agent NF-κB, thereby exerting its anti-inflammatory properties.25,33,35,37-39 The p38-MAPK and NF-κB pathways regulate inflammation and catabolism in OA and their activation starts multiple cascades that start inflammatory and immune responses leading to the higher production of inflammatory factors.39 Therefore, p38-MAPK and NF-κB suppressors are assumed to have therapeutic properties and are favorable in OA. Moreover, pomegranate fruit extract blocks IL-1β-stimulated proteoglycan breakdown and MMPs production, thereby blocking collagen and joint destruction.39 Anti-inflammatory properties of pomegranate in OA can further be reinforced via suppressing NO generation.25,27,28,33 NO is a proinflammatory parameter secreted from the activated...
Inflammatory cytokines in chondrocytes augment iNOS function and NO synthesis. Higher NO levels induce chondrocyte apoptosis. Thus, agents that inhibit additional NO synthesis may exert therapeutic effects via suppressing cartilage deterioration.

Another possible mechanism for the benefits of pomegranate in OA is antioxidant and free radicals scavenging properties. It appears that antioxidant function of pomegranate is mainly related to phenolic agents (e.g. punicalagin, ellagic acid, anthocyanins). These agents remove free radicals and suppress lipid oxidation in vitro. Pomegranate polyphenolics go through redox reactions because phenolic hydroxyl groups donate hydrogen to reducing factors. Phenolic agents present in pomegranate peel extract have strong proton-donating potential together with the hydroxyl groups to fixate free radicals, thereby scavenging DPPH radicals. Pomegranate extract has been suggested to remove free oxygen and nitrogen radicals, thereby decreasing oxidative and nitrosative stress as well as lipid peroxidation in animals and increasing antioxidant capacity in individuals. Pomegranate peel extract can augment or preserve the free radicals scavenging activity of the antioxidant enzymes including SOD, GPx, and catalase causing decrease in lipid peroxidation.

SOD and GPx function as a defense system against ROS. The SOD counteracts superoxide anion which has a key role in OA inflammation. GPx is another significant enzyme that detoxifies peroxides and hydroperoxides. Pomegranate juice consumption in humans can lead to a non-remarkable elevation in TAC and paraoxonase and a non-remarkable reduction in MDA. Enhanced paraoxonase concentrations following pomegranate consumption may illustrate antioxidant features of pomegranate polyphenols. As mentioned before, oxidative stress is the result of excessive ROS production that may lead to irreversible damage to the chondrocytes and induces cell death via apoptosis or necrosis. It seems that pomegranate decreases pro-apoptotic protein Bax levels and caspase-3 activity and increases anti-apoptotic protein Bcl-2 levels in OA chondrocytes, thereby inhibiting apoptosis and exerting beneficial effects in OA.

Figure 3 demonstrates the mechanisms and pharmacologic effects of pomegranate in OA.

The limitation of our review included limited human investigations whilst the experimental investigations were desirable. Also, considering risk of bias assessment, experimental studies showed unclear risk of bias regarding randomization, allocation concealment, and blinding due to the lack of reporting. The strength of our review was to study the relevant in vitro, animal, and human investigations in a systematic way. Also, no limitation was considered regarding language and time.

As a conclusion, in vitro, animal, and human investigations entered in current systematic review depicted the benefits of pomegranate in OA by ameliorating clinical features and biochemical markers like inflammatory, oxidative stress, and apoptotic parameters and contributed to the hypothesis that pomegranate may possess the potential to be helpful in managing OA. Current systematic review was just a depiction of available articles about the usefulness of pomegranate consumption in OA. Additional researches are required to support the beneficial properties of pomegranate in OA.

**Figure 3.** Mechanisms and pharmacological effects of pomegranate in osteoarthritis
Acknowledgements

We thank the Research Vice-Chancellor of Tabriz University of Medical Sciences, Tabriz, Iran for financial support (Grant No. 67834).

Funding

This research was financially supported by a Grant from Research Vice-Chancellor of Tabriz University of Medical Sciences, Tabriz, Iran (Grant No. 67834).

Competing interests

One of the authors (ZJ) is the member of editorial board of Health Promotion Perspective journal. The other author (AMM) declared no conflict of interest.

Ethical approval

Not applicable.

Authors’ contributions

AMM contributed to the conceptualization and study design, data collection and interpretation, data extraction, manuscript drafting and its editing, and manuscript revision. ZJ helped in data collection and interpretation, data extraction, quality assessment of papers, manuscript drafting and its revision. All authors have read and approved the submitted and revised final version of the manuscript and confirm that it is not published elsewhere and is not copied from other papers.

Disclaimer

The authors claim that no part of this paper is copied from other sources.

Availability of data and material

The data is available from corresponding author (AMM) upon receiving the request.

References

1. Hunter DJ, Bierna-Žeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745-59. doi: 10.1016/s0140-6736(19)30417-9.
2. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10121):1211-59. doi: 10.1016/s0140-6736(17)32154-2.
3. Krasnokutsky S, Attur M, Palmer G, Samuels J, Abramson SB. Current concepts in the pathogenesis of osteoarthritis. Osteoarthriris Cartilage. 2008;16 Suppl 3:51-3. doi: 10.1016/j.joca.2008.06.025.
4. Guan VX, Mobasher A, Probst YC. A systematic review of osteoarthritis prevention and management with dietary phytochemicals from foods. Maturitas. 2019;122:205-11. doi: 10.1097/MAT.0000000000001005.
5. van der Kraan PM, van den Berg WB. Anabolic and destructive mediators in osteoarthritis. Curr Opin Clin Nutr Metab Care. 2000;3(3):205-11. doi: 10.1097/00000751-199905000-00007.
6. Haseeb A, Haqqi TM. Immunopathogenesis of osteoarthritis. Clin Immunol. 2013;146(3):185-96. doi: 10.1016/j.clim.2012.12.011.
7. Lepetèsos P, Papavasiillow AG. ROS/oxidative stress signaling in osteoarthritis. Biochim Biophys Acta. 2016;1862(4):576-91. doi: 10.1016/j.bbadis.2016.01.003.
8. Phillips CR, Brasington RD Jr. Osteoarthritis treatment update: are NSAIDs still in the picture? J Musculoskelet Med. 2010;27(2):65-71.
9. Kolahi S, Malek Mahdavi A, Mahdavi R, Lak S. Effect of L-carnitine supplementation on clinical symptoms in women with osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Eur J Integr Med. 2015;7(5):540-6. doi: 10.1016/j.eujim.2015.04.001.
10. World Health Organization (WHO). WHO Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems. Geneva, Switzerland: WHO; 2004.
11. Akhtar N, Haqqi TM. Current nutraceuticals in the management of osteoarthritis: a review. Ther Adv Musculoskelet Dis. 2012;4(3):181-207. doi: 10.1177/1759720x11436238.
12. Shen CL, Smith BJ, Lo DF, Chyu MC, Dunn DM, Chen CH, et al. Dietary polyphenols and mechanisms of osteoarthritis. J Nutr Biochem. 2012;23(11):1367-77. doi: 10.1016/j.jnutbio.2012.04.001.
13. Jurenka JS. Therapeutic applications of pomegranate (Punica granatum L.): a review. Altern Med Rev. 2008;13(2):128-44.
14. Viuda-Martos M, Fernández-López J, Pérez-Álvarez JA. Pomegranate and its many functional components as related to human health: a review. Compr Rev Food Sci Food Saf. 2010;9(6):635-54. doi: 10.1111/j.1541-4337.2010.00131.x.
15. Vroegrijk IG, van Diepen JA, van den Berg S, Westbroek I, Keizer H, Gambelli L, et al. Pomegranate seed oil, a rich source of puninic acid, prevents diet-induced obesity and insulin resistance in mice. Food Chem Toxicol. 2011;49(6):1426-30. doi: 10.1016/j.fct.2011.03.037.
16. El-Nemr SE, Ismail IA, Ragab M. Chemical composition of juice and seeds of pomegranate fruit. Food/Nahrung. 1990;34(7):601-6. doi: 10.1002/food.19900340706.
17. Johanssonmeier SD, Harris GK. Pomegranate as a functional food and nutraceutical source. Annu Rev Food Sci Technol. 2011;2:181-201. doi: 10.1146/annurev-food-030810-153709.
18. Puneeth HR, Sharath Chandra SP. A review on potential therapeutic properties of pomegranate (Punica granatum L.). Plant Sci Today. 2020;7(1):9-16. doi: 10.14799/jcpta.2020.7.1.619.
19. Vidal A, Fallarero A, Peña BR, Medina ME, Gia B, Rivera F, et al. Studies on the toxicity of Punica granatum L. (Punicaeae) whole fruit extracts. J Ethnopharmacol. 2003;89(2-3):295-300. doi: 10.1016/j.jep.2003.09.001.
20. Cerdó B, Cerón JJ, Tomás-Barberán FA, Espín JC. Repeated oral administration of high doses of the pomegranate ellagitannin punicalagin to rats for 37 days is not toxic. J Agric Food Chem. 2003;51(11):3493-501. doi: 10.1021/jf020842c.
21. Heber D, Seeram NP, Wyatt H, Henning SM, Zhang Y, Ogden LG, et al. Studies on safety and antioxidant activity of a pomegranate ellagitannin-enriched polyphenol dietary supplement in overweight individuals with increased waist size. J Agric Food Chem. 2007;55(24):10050-4. doi: 10.1021/jf071689v.
22. Aviram M, Rosenbлат M, Gaitini D, Nitecki S, Hoffman A, Domfeld L, et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima media thickness, blood pressure and LDL oxidation. Clin Nutr. 2004;23(3):423-33. doi: 10.1016/j.clinu.2003.10.002.
23. Shivnath N, Rawat V, Siddiqui S, Verma S, Gupta P, Rais J, et al. Antiosteoarthritic effect of Punica granatum L. peel extract on collagenase induced osteoarthritis rat by modulation of COL-2, MMP-3, and COX-2 expression. Environ Toxicol. 2020. doi: 10.1002/tox.23005.
24. Kong J, Wang J, Gong X, Zheng X, Chen T. Punicagalin inhibits tert-butyl hydroperoxide-induced apoptosis and extracellular matrix degradation in chondrocytes by activating autophagy and ameliorates murine osteoarthritis. Drug Des Devel Ther. 2020;14:5521-33. doi: 10.2147/dddt.s282932.
25. Lin Z, Lin C, Fu C, Lu H, Jin H, Chen Q, et al. The protective effect of Ellagic acid (EA) in osteoarthritis: an in vitro and in vivo study. Oncotarget. 2016;7(33):54975-88. doi: 10.18632/oncotarget.11493.
vivo study, Biomed Pharmacother. 2020;125:109845. doi: 10.1016/j.biopha.2020.109845.

26. Elder SH, Mosher ML, Jarquin P, Smith P, Chironis A. Effects of short-duration treatment of cartilage with punicalagin and genipin and the implications for treatment of osteoarthritis. J Biomed Mater Res B Appl Biomater. 2021;109(6):818-28. doi: 10.1002/jbm.b.34747.

27. Fu X, Gong LF, Wu YF, Lin L, Zhan BY, Wu L, et al. Urolithin A targets the PI3K/Akt/NF-κB pathways and prevents IL-1β-induced inflammatory response in human osteoarthritis: in vitro and in vivo studies. Food Funct. 2019;10(9):6135-46. doi: 10.1039/c9fo01332f.

28. Lee CJ, Chen LG, Liang WL, Hsieh MS, Wang CC. Inhibitory extracts of punicinagin from Punica granatum against type II collagenase-induced osteoarthritis. J Funct Foods. 2018;41:216-22. doi: 10.1016/j.jff.2017.12.026.

29. Choi BK, Ku SK, Kang SJ, Park HR, Sung MS, Lee YJ, et al. Anti-osteoarthritis effects of a combination of pomegranate concentrate powder, Eucommiae cortex and Achyranthis radix in rats. J Korean Med. 2018;39(4):86-113. doi: 10.13048/jkm.18037.

30. Choi BK, Ku SK, Kang SJ, Park HR, Sung MS, Lee YJ, et al. Selection of the optimal herbal composition of pomegranate concentrated powder from aqueous extracts of Eucommiae cortex and Achyranthis radix to treat osteoarthritis in rats. J Korean Med. 2017;38(4):11-40. doi: 10.13048/jkm.17037.

31. Akhtar N, Khan NM, Ashraf OS, Haqqi TM. Inhibition of cartilage degradation and suppression of PGE(2) and MMPs expression by pomegranate fruit extract in a model of posttraumatic osteoarthritis. Nutrition. 2017;33:1-13. doi: 10.1016/j.nut.2016.08.004.

32. Hadipour-Jahromy M, Mozaffari-Kermani R. Chondroprotective effects of pomegranate juice on monoiodoacetate-induced osteoarthritis of the knee joint of mice. Phytother Res. 2010;24(2):182-5. doi: 10.1002/ptr.2800.

33. Ding SL, Pang ZY, Chen XM, Li Z, Liu X, Zhai QL, et al. Urolithin a attenuates IL-1β-induced inflammatory responses and cartilage degradation via inhibiting the MAPK/NFκB signaling pathways in rat articular chondrocytes. J Inflamm (Lond). 2020;17:13. doi: 10.1186/s12950-020-00428-4.

34. Taherian, Maghsoudi H, Vaziri A, Alebouyeh M. Investigation of punicin acid effects on matrix metalloproteinase gene expression in bovine fibroblast-like synoviocytes as a model of osteoarthritis. J Med Plants. 2018;17(6):31-44.

35. Haseeb A, Khan NM, Ashraf OS, Haqqi TM. A polyphenol-rich pomegranate fruit extract suppresses NF-κB and IL-6 expression by blocking the activation of IKKβ and NIK in primary human chondrocytes. Phytother Res. 2017;31(5):778-82. doi: 10.1002/ptr.5799.

36. Choi BK, Ku SK, Kang SJ, Park HR, Sung MS, Lee YJ, et al. Anti-osteoarthritis effects of pomegranate, Eucommiae cortex and Achyranthis radix extracts on the primary cultured rat articular chondrocytes. Journal of Society of Preventive Korean Medicine. 2017;21(3):87-98. doi: 10.25153/ spkkm.2017.21.3.009.

37. Haseeb A, Chen D, Haqqi TM. Delphinidin inhibits IL-1β-induced activation of NF-κB by modulating the phosphorylation of IRAK-1(ser376) in rat articular chondrocytes. Rheumatology (Oxford). 2013;52(6):998-1008. doi: 10.1093/rheumatology/ket363.

38. Rasheed Z, Akhtar N, Haqqi TM. Pomegranate extract inhibits the interleukin-1β-induced activation of MKK-3, p38α-MAPK and transcription factor RUNX-2 in human osteoarthritis chondrocytes. Arthritis Res Ther. 2010;12(5):R195. doi: 10.1186/ar3136.

39. Ahmed S, Wang N, Hafeez BB, Chervuuk VK, Haqqi TM. Punica granatum L. extract inhibits IL-1beta-induced expression of matrix metalloproteinases by inhibiting the activation of MAP kinases and NF-kappaB in human chondrocytes in vitro. J Nutr. 2005;135(9):2096-2102. doi: 10.1093/jn/135.9.2096.

40. Khadem Haghighian M, Rafraf M, Hemmati S, Haghravan S, Asghari-Jafarabadi M. Effects of pomegranate (Punica granatum L.) peel extract supplementation on serum lipid profile and oxidative stress in obese women with knee osteoarthritis: a double blind, randomized, placebo controlled study. Adv Integr Med. 2021;8(2):107-13. doi: 10.1016/j.aimed.2020.05.001.

41. Rafraf M, Hemmati S, Asghari Jafarabadi M, Moghaddam A, Khadem Haghighian M. Pomegranate (Punica granatum L.) peel hydroalcoholic extract supplementation reduces pain and improves clinical symptoms of knee osteoarthritis: a randomized double-blind placebo controlled study. Iran Red Crescent Med J. 2017;19(1):e38577. doi: 10.5812/irjc.38577.

42. Khadem Haghighian MK, Rafraf M, Moghaddam A, Hemmati S, Jafarabadi MA, Gargari BP. Pomegranate (Punica granatum L.) peel hydro alcoholic extract ameliorates cardiovascular risk factors in obese women with dyslipidemia: a double blind, randomized, placebo controlled pilot study. Eur J Integr Med. 2016;8(5):676-82. doi: 10.1016/j.eujim.2016.06.010.

43. Ghoochani N, Karandish M, Mowla K, Haghhighizadeh MH, Jalali MT. The effect of pomegranate juice on clinical signs, matrix metalloproteinases and antioxidant status in patients with knee osteoarthritis. J Sci Food Agric. 2016;96(13):4377-81. doi: 10.1002/jsfa.7647.

44. Ghoochani N, Karandish M, Mowla K, Haghhighizadeh MH, Khorami M, Jalali MT. The Effects of pomegranate juice on proinflammatory cytokines and physical function in patients with knee osteoarthritis. Jentashapir J Cell Mol Biol. 2015;6(5):e26558. doi: 10.17795/jcmbr-26558.

45. Moher D, Shamseer L, Clarke M, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. doi: 10.1186/2046-4053-4-1.

46. Malek Mahdavi A, Seyedasadadi N, Javadvila Z. Potential effects of pomegranate (Punica granatum) on rheumatoid arthritis: a systematic review. Int J Clin Pract. 2021;75(8):e13999. doi: 10.1111/ijcp.13999.

47. Yang L, Fan C, Shi T, Wang S. Punicin alleviates TNF-α and IL-1β-induced chondrocyte dysfunction and cartilage metabolism via mediating FOXO3 signaling axis. J Food Biochem. 2021:e13755. doi: 10.1111/jfbc.13755.

48. Ansari MY, Ahmad N, Haqqi TM. Oxidative stress and inflammation in osteoarthritis pathogenesis: role of polyphenols. Biomed Pharmacother. 2020;129:110452. doi: 10.1016/j.biopha.2020.110452.

49. Bolduc JA, Collins JA, Loeper RF. Reactive oxygen species, aging and articular cartilage homeostasis. Free Radic Biol Med. 2019;132:73-82. doi: 10.1016/j.freeradbiomed.2018.08.038.

50. Li Y, Wu Y, Jiang K, Han W, Zhang J, Xie L, et al. Mangiferin prevents TBHP-induced apoptosis and ECM degradation in mouse osteoarthritic chondrocytes via restoring autophagy and ameliorates murine osteoarthritis. Oxid Med Cell Longev. 2019;2019:8783197. doi: 10.1155/2019/8783197.

51. Zheng G, Zhan Y, Li X, Fan Z, Zheng F, Zhang Z, et al. TFEB, a potential therapeutic target for osteoarthritis via autophagy regulation. Cell Death Dis. 2018;9(9):858. doi: 10.1038/s41419-018-0909-y.

52. Lee CJ, Chen LG, Liang WL, Wang CC. Anti-inflammatory effects of Punica granatum Linne in vitro and in vivo. Food Sci Technol. 2011;6(2):315-22. doi: 10.1016/j.foodchem.2009.04.123.

53. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004;18(18):2195-224. doi: 10.1101/gad.128704.

54. Seo WG, Pae HO, Oh GS, Choi KY, Kwon TO, Yun YG, et al. Inhibitory effects of methanol extract of Cyperus rotundus rhizomes on nitric oxide and superoxide productions by murine
macrophage cell line, RAW 264.7 cells. J Ethnopharmacol. 2001;76(1):59-64. doi: 10.1016/s0378-8741(01)00221-5.

55. Blanco FJ, Ochs RL, Schwarz H, Lotz M. Chondrocyte apoptosis induced by nitric oxide. Am J Pathol. 1995;146(1):75-85.

56. Shukla M, Gupta K, Rasheed Z, Khan KA, Haqqi TM. Bioavailable constituents/metabolites of pomegranate (Punica granatum L) preferentially inhibit COX2 activity ex vivo and IL-1beta-induced PGE2 production in human chondrocytes in vitro. J Inflamm (Lond). 2008;5:9. doi: 10.1186/1476-9255-5-9.

57. Gil MI, Tomás-Barberán FA, Hess-Pierce B, Holcroft DM, Kader AA. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem. 2000;48(10):4581-9. doi: 10.1021/jf000404a.

58. Noda Y, Kaneyuki T, Mori A, Packer L. Antioxidant activities of pomegranate fruit extract and its anthocyanidins: delphinidin, cyanidin, and pelargonidin. J Agric Food Chem. 2002;50(1):166-71. doi: 10.1021/jf0108765.

59. Brand-Williams W, Cuvelier ME, Berset C. Use of a free radical method to evaluate antioxidant activity. LWT. 1995;28(1):25-30. doi: 10.1016/s0023-6438(95)80008-5.

60. Nair RK, Haridas A, Ezhuthupurakkal DR. Diversity and comparative account on phytochemical and antioxidant properties of two varieties of Musa, Nendran and Kunnan. South Indian J Biol Sci. 2016;2(1):203-6. doi: 10.22205/sijbs2016/v2/i1/100396.

61. Rosenblat M, Volkova N, Coleman R, Aviram M. Pomegranate byproduct administration to apolipoprotein e-deficient mice attenuates atherosclerosis development as a result of decreased macrophage oxidative stress and reduced cellular uptake of oxidized low-density lipoprotein. J Agric Food Chem. 2006;54(5):1928-35. doi: 10.1021/jf0528207.

62. Guo CJ, Wei JY, Yang JJ, Xu J, Li YF, Pang W. The comparative study on improvement of antioxidant function in the elderly by consumption of pomegranate or apple juices. Ying Yang Xue Bao. 2007;29(3):292-4.

63. Madrigal-Carballo S, Rodriguez G, Krueger CG, Dreher M, Reed JD. Pomegranate (Punica granatum) supplements: authenticity, antioxidant and polyphenol composition. J Funct Foods. 2009;1(3):324-9. doi: 10.1016/j.jff.2009.02.005.

64. Chidambara Murthy KN, Jayaprakash GA, Singh RP. Studies on antioxidant activity of pomegranate (Punica granatum) peel extract using in vivo models. J Agric Food Chem. 2002;50(17):4791-5. doi: 10.1021/jf0255735.

65. Alfonso V, Champy R, Mitrovic D, Collin P, Lonri A. Reactive oxygen species and superoxide dismutases: role in joint diseases. Joint Bone Spine. 2007;74(4):324-9. doi: 10.1016/j.jbspin.2007.02.002.

66. Jurković S, Osredkar J, Marc J. Molecular impact of glutathione peroxidases in antioxidant processes. Biochim Biophys Acta. 2008;18(2):162-74. doi: 10.1161/bbm.2008.016.

67. Morvaridzadeh M, Sepidarkish M, Daneshzad E, Akbari A, Mobini GR, Heshmati J. The effect of pomegranate on oxidative stress parameters: a systematic review and meta-analysis. Complement Ther Med. 2020;48:102252. doi: 10.1016/j.ctim.2019.102252.

68. Lepetsos P, Papavassiliou AG. ROS/oxidative stress signaling in osteoarthritis. Biochim Biophys Acta. 2016;1862(4):576-91. doi: 10.1016/j.bbadis.2016.01.003.